{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"RACIN","nct_id":"NCT03728179","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=racin-nct03728179. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RACIN","arms":[{"description":"0,5 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"1 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin","label":"Cohort 2","type":"EXPERIMENTAL"},{"description":"1 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib","label":"Cohort 3a","type":"EXPERIMENTAL"},{"description":"2 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib","label":"Cohort 4a","type":"EXPERIMENTAL"},{"description":"Recommended Phase Ib RT dose (RP1bD) + Nivolumab + Ipilimumab or Cyclophosphamide + Celecoxib","label":"Phase I b","type":"EXPERIMENTAL"},{"description":"1 Gy of RT + Ipilimumab + Nivolumab + Celecoxib","label":"Cohort 3b","type":"EXPERIMENTAL"},{"description":"2 Gy of RT + Ipilimumab + Nivolumab + Celecoxib","label":"Cohort 4b","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-10-27","type":"ACTUAL"},"conditions":["Solid Tumor, Adult"],"enrollment":{"count":40,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib","otherNames":[],"type":"COMBINATION_PRODUCT"}],"last_update":"2024-02-20","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","official_title":"RACIN, A Phase I Study of the Combination of Nivolumab Associated With Low-dose Radiation, Aspirin/ Celecoxib, and Either Ipilimumab or Low-dose Cyclophosphamide, Followed by Nivolumab Maintenance, in Patients With Advanced, TIL-negative Solid Tumors","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-10-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phases Ia and Ib: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","timeFrame":"3.5 years"},{"measure":"Maximum Tolerated dose (MTD) or recommended phase Ib dose of low-dose irradiation for radio-immunotherapy combination (RP1bD).","timeFrame":"3.5 years"}],"references":[],"start_date":{"date":"2019-01-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"RACIN in Patients With Advanced TIL-negative Solid Tumors","url":"https://clinicaltrials.gov/study/NCT03728179"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/racin-nct03728179"}